Efficacy and Safety of Alflutinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer Patients With T790M

Phase 2 Terminated 220 enrolled Allist Pharmaceuticals, Inc.

NaSingle-groupOpen-labelTreatment

Summary

This study is conducted to evaluate the efficacy and safety of Alflutinib in locally advanced or metastatic non-small cell lung cancer patients harbouring T790M mutation

Timeline

Start: 2018-04-30
Primary completion: 2021-04-21
Completion: 2024-03-14

Publications

Shi Y, Hu X, Zhang S, Lv D, Wu L, Yu Q, Zhang Y, Liu L, Wang X, Cheng Y, Ma Z, Niu H, Wang D, Feng J, Huang C, Liu C, Zhao H, Li J, Zhang X, Jiang Y, Gu C. Efficacy, safety, and genetic analysis of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small-cell lung cancer: a phase 2b, multicentre, single-arm, open-label study. Lancet Respir Med. 2021 Aug;9(8):829-839. doi: 10.1016/S2213-2600(20)30455-0. Epub 2021 Mar 26.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Firmonertinib	Small molecule	80 mg	—
Subject	Firmonertinib	Small molecule	160 mg	—

Indications

No indication recorded.